Equities research analysts at StockNews.com began coverage on shares of 22nd Century Group (NASDAQ:XXII – Get Free Report) in a report released on Wednesday. The brokerage set a “sell” rating on the biotechnology company’s stock.
22nd Century Group Trading Down 16.4 %
Shares of NASDAQ XXII opened at $0.18 on Wednesday. The company has a fifty day moving average price of $0.47 and a 200 day moving average price of $3.62. The firm has a market cap of $1.49 million, a PE ratio of 0.00 and a beta of 1.41. 22nd Century Group has a 1-year low of $0.18 and a 1-year high of $15.84.
22nd Century Group (NASDAQ:XXII – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. The firm had revenue of $7.95 million for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 275.12%.
Institutional Trading of 22nd Century Group
About 22nd Century Group
22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.
Read More
- Five stocks we like better than 22nd Century Group
- Investing In Preferred Stock vs. Common Stock
- Why Lennar Stock Could Be the Best Play in the Housing Market
- What is the Shanghai Stock Exchange Composite Index?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- How to Read Stock Charts for Beginners
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for 22nd Century Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group and related companies with MarketBeat.com's FREE daily email newsletter.
